Exploiting synergy: immune-based combinations in the treatment of prostate cancer. - Wikidata - awgldk - TriplyDB

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

http://www.wikidata.org/entity/Q34687216

about

Immune Infiltration and Prostate Cancer Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical model Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction.Immune Therapy for Prostate Cancer.Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells.Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.Editorial: Advances in Combination Tumor Immunotherapy.

P2860

Q26798412-9D589987-80F6-4C4E-8EC1-B13122F94760 Q33728672-9F93B414-61FE-4AD4-9ACD-1C034D2024F0 Q37708841-CC096B0F-9EA6-42A0-A02F-7CBE087D15C9 Q38982667-28A7502D-6778-4513-A278-A02D525B4BE5 Q39559063-8CA3A2D2-32B4-4CE5-9E66-215E379D005D Q41636538-5A0548EC-6797-4DD5-B554-57F2238A0BD9 Q42047687-1D1CA5C8-4C88-46D1-8F98-E06AFA08519F

P2860

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

http://www.wikidata.org/entity/Q34687216

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@ast

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@en

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@nl

type

label

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@ast

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@en

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@nl

prefLabel

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@ast

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@en

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@nl

P1433

Q34687216-80AE17DB-6569-4319-8426-4392DE0DC5B6

P1476

Q34687216-FABB0FB0-3F73-4375-9425-2AF1EF060779

P2093

Q34687216-12E63A96-EBB7-46EF-9BF7-97E74BE496CA

Q34687216-54A92E72-31BC-42A4-868D-BA729A156DFF

Q34687216-638A78B1-5B7D-4C73-AF69-11FE155376B1

Q34687216-63F4871A-0FBD-4178-9765-2CF426ED7FAA

Q34687216-BDE7DA26-2153-43BE-AD86-D78E94C1216C

P2860

Q34687216-072BEECE-D865-4E8D-AF60-BE0C4B1C66B0

Q34687216-0AA47F50-C08E-4DF1-BD8C-7B16CF77ADE8

Q34687216-0CDC2A5F-C2C9-4C52-940F-8B18118C0579

Q34687216-0E23CE8E-23CC-4518-A192-CA65F234B0BC

Q34687216-0EEBDD67-F55F-4900-8930-387FF37239FF

Q34687216-1861DC3E-3958-4D2F-A8C4-15A0F80DC7A5

Q34687216-1BF87FB2-BEF6-4C65-9CDF-B5BC17C4DC5A

Q34687216-1CE7067D-4063-4F4C-961B-05FAA6B8F717

Q34687216-1D449F54-6AE4-47CE-8216-537867457F74

Q34687216-1F6AA2AC-59BC-4DFE-AD36-BA0AA6DCFB1D

P304

Q34687216-42565C08-BE1F-4C6C-9910-702B1251A7AA

P31

Q34687216-069FD166-7685-491D-BF02-A8512B3210FF

P356

Q34687216-1EDCB53B-6BEA-4AC2-929C-8C9AF87231C1

P478

Q34687216-31BB2298-E841-42AA-8BC8-9D1552BBA26B

P577

Q34687216-ED1595E2-0226-4AB2-A49E-44C619891106

P5875

Q34687216-9E203649-8898-4ED5-A1AD-A66EF175665D

P698

Q34687216-A8D56418-B51D-4920-A43E-07E2FB5A54C7

P932

Q34687216-9069CEC1-3591-4817-AB92-13E4ADAD529F

P356

FONC.2014.00351

P1433

Frontiers in Oncology

P1476

Exploiting synergy: immune-based combinations in the treatment of prostate cancer.

@en

P2093

Christopher R Heery

http://www.w3.org/2001/XMLSchema#string

James L Gulley

http://www.w3.org/2001/XMLSchema#string

Mauricio Burotto

http://www.w3.org/2001/XMLSchema#string

Nishith Singh

http://www.w3.org/2001/XMLSchema#string

Ravi A Madan

http://www.w3.org/2001/XMLSchema#string

P2860

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

The blockade of immune checkpoints in cancer immunotherapy

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Cancer statistics, 2014

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

The B7 family revisited

P304

351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2014.00351

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270655642

http://www.w3.org/2001/XMLSchema#string

P698

25566495

http://www.w3.org/2001/XMLSchema#string

P932

4264488

http://www.w3.org/2001/XMLSchema#string